Impact of Nonmedical Adalimumab Switches in a Rheumatology Patient Population
Stefania DelPrete, Krista Dessureault, Molly Bachman, Morgan Merchand, Derek Devine, Amanda G Kennedy, Julie MacDougall · 2026
Read Impact of Nonmedical Adalimumab Switches in a Rheumatology Patient Population by Stefania DelPrete, Krista Dessureault, Molly Bachman, Morgan Merchand, Derek Devine, Amanda G Kennedy, Julie MacDougall (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13530030.txt.
Description
Stefania DelPrete and co-authors study what happens when rheumatology patients are switched from adalimumab to a biosimilar for nonmedical reasons. Their 2026 paper deals with insurance-mandated switches in a real patient population.
Adalimumab is an anti-tumor necrosis factor drug approved in 2002 for various rheumatic diseases. New biosimilars raise questions about real-world efficacy and cost savings. The team ran a retrospective cohort study of patients whose payers mandated a switch. The main outcome was change in disease activity, taken from provider notes before the switch and at follow-up. A second aim was the financial impact of the switches.
Catalog record
| CREATOR | Stefania DelPrete, Krista Dessureault, Molly Bachman, Morgan Merchand, Derek Devine, Amanda G Kennedy, Julie MacDougall |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |